Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amendments to pregnancy labeling

Executive Summary

A proposed rule to alter labeling concerning the use of prescription drugs in pregnancy is under review of the White House Office of Management and Budget as of Jan. 3. The proposal, titled "Content and Format of Labeling for Human Prescription Drugs and Biologics: Requirements for Pregnancy and Lactation Labeling," would revise labeling due to concerns expressed by stakeholders at a public hearing, in focus groups, and in several advisory committee meetings that the letter categories (A, B, C, D, X) currently used to characterize the risk to the fetus of using the drug during pregnancy are confusing, overly simplistic and not adequate to communicate risks effectively...

You may also be interested in...



Pregnancy labeling due date nears

A proposed regulation on the format and content of drug labeling to address pregnancy and lactation issues could be published this month, according to the HHS Semiannual Regulatory Agenda. Published in the May 5 Federal Register, the agenda sets a May 2008 target date for the proposed rule, which is intended to convey more clearly the risks to a fetus or newborn from a mother's use of a drug (1"The Pink Sheet," Jan. 7, 2008, In Brief)

PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports

France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel